The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides

Yu Sun; Yuanya Jing; Mengwen Huang; Jinyun Ma; Xiaoyan Peng; Jinying Wang; Guoling Li; Xiaodong Cheng

doi:10.1016/j.jneuroim.2019.03.019

The PD-1/PD-Ls pathway is up-regulated during the suppression of experimental autoimmune encephalomyelitis treated by Astragalus polysaccharides

J Neuroimmunol. 2019 Jul 15:332:78-90. doi: 10.1016/j.jneuroim.2019.03.019. Epub 2019 Apr 1.

Authors

Yu Sun¹, Yuanya Jing², Mengwen Huang², Jinyun Ma¹, Xiaoyan Peng¹, Jinying Wang¹, Guoling Li¹, Xiaodong Cheng³

Affiliations

¹ Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China.
² School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
³ Yue-yang Hospital of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China; School of Life Sciences and Technology, Tongji University, Shanghai 200092, China. Electronic address: chengxiaodong@shutcm.edu.cn.

PMID: 30981049
DOI: 10.1016/j.jneuroim.2019.03.019

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of CNS. Astragalus polysaccharides (APS), the main active extract from astragalus membranaceus which is a kind of traditional Chinese medicinal herb, is associated with a variety of immunomodulatory activities. We have evaluated the therapeutic effects of APS in the animal model of MS, experimental autoimmune encephalomyelitis (EAE). It was found that APS could effectively alleviate EAE through inhibiting MOG_35-55-specific T cell proliferation and reducing the expression of proinflammatory cytokines, which is mediated by up-regulating the expression of PD-1/PD-Ls signaling pathway. Our results demonstrated that EAE could be suppressed significantly by APS administration. It indicated that APS might be a potential of developing innovative drug for the therapy of MS.

Keywords: Astragalus polysaccharides; CNS; EAE; PD-1/PD-Ls molecules; T lymphocytes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Inflammatory Agents / pharmacology
Anti-Inflammatory Agents / therapeutic use*
Astragalus propinquus / chemistry*
B7-H1 Antigen / biosynthesis*
B7-H1 Antigen / genetics
B7-H1 Antigen / physiology
Cytokines / biosynthesis
Cytokines / genetics
Encephalomyelitis, Autoimmune, Experimental / chemically induced
Encephalomyelitis, Autoimmune, Experimental / drug therapy*
Female
Inflammation
Mice
Mice, Inbred C57BL
Myelin-Oligodendrocyte Glycoprotein / toxicity
Peptide Fragments / toxicity
Phytotherapy*
Plant Gums / pharmacology
Plant Gums / therapeutic use*
Programmed Cell Death 1 Ligand 2 Protein / biosynthesis*
Programmed Cell Death 1 Ligand 2 Protein / genetics
Programmed Cell Death 1 Ligand 2 Protein / physiology
Programmed Cell Death 1 Receptor / biosynthesis*
Programmed Cell Death 1 Receptor / genetics
Programmed Cell Death 1 Receptor / physiology
RNA, Messenger / biosynthesis
RNA, Messenger / genetics
Signal Transduction / drug effects*
Spinal Cord / drug effects
Spinal Cord / immunology
Spinal Cord / pathology
T-Lymphocyte Subsets / drug effects
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / pathology
Up-Regulation / drug effects

Substances

Anti-Inflammatory Agents
B7-H1 Antigen
Cd274 protein, mouse
Cytokines
Myelin-Oligodendrocyte Glycoprotein
Pdcd1 protein, mouse
Pdcd1lg2 protein, mouse
Peptide Fragments
Plant Gums
Programmed Cell Death 1 Ligand 2 Protein
Programmed Cell Death 1 Receptor
RNA, Messenger
myelin oligodendrocyte glycoprotein (35-55)